You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Nexavar®.

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prospective, Non-interventional, Post-authorization Safety Study

Active, not recruiting
  • Thyroid Carcinoma
  • Sorafenib (Nexavar, BAY43-9006)
  • Multiple Locations, Japan
    (unnamed)
Aug 18, 2022

Hepatocellular Carcinoma Trial in Mansoura (Sorafenib Tablets)

Recruiting
  • Hepatocellular Carcinoma
  • Sorafenib Tablets
  • Mansoura, El-Dakahelia, Egypt
    Mansoura University Hospital
Sep 3, 2023

Advanced Cancer Trial in Houston (Temsirolimus, Bevacizumab, Paclitaxel)

Active, not recruiting
  • Advanced Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Oct 11, 2022

Pharmacokinetics, Bioavailability Trial in Nottingham (Sorafenib - Period 1, XS005 Sorafenib Capsule A - Period 1, XS005

Completed
  • Pharmacokinetics
  • Bioavailability
  • Sorafenib - Period 1
  • +8 more
  • Nottingham, United Kingdom
    Quotient Sciences
Jul 20, 2023

Hepatocellular Cancer Trial in San Antonio (Sorafenib (SOR), Hydroxychloroquine (HCQ))

Recruiting
  • Hepatocellular Cancer
  • Sorafenib (SOR)
  • Hydroxychloroquine (HCQ)
  • San Antonio, Texas
    University of Texas Health Cancer Center
Sep 16, 2022

Hepatocellular Carcinoma, Advanced Cancer Trial in Charleston, Tainan, Taipei (Sorafenib, CVM-1118)

Terminated
  • Hepatocellular Carcinoma
  • Advanced Cancer
  • Charleston, South Carolina
  • +2 more
Jan 6, 2023

Called ROCURS, to Learn About COVID-19 Related Outcomes in

Active, not recruiting
  • Malignant Solid Tumors
  • +2 more
  • Whippany, New Jersey
    Bayer
Feb 2, 2023

Glioblastoma, Recurrent Adult Brain Tumor, Malignant Glioma Trial in Richmond (sorafenib tosylate, valproic acid, sildenafil

Active, not recruiting
Has Results
  • Glioblastoma
  • +3 more
  • sorafenib tosylate
  • +2 more
  • Richmond, Virginia
    Virginia Commonwealth University/Massey Cancer Center
Mar 21, 2022

Melanoma (Skin) Trial in Philadelphia (sorafenib tosylate, temozolomide)

Completed
Has Results
  • Melanoma (Skin)
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jun 13, 2022

The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or

Recruiting
  • Acute Leukemia
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 28, 2022

Solid Tumor Trial in Taipei (MG005)

Completed
  • Solid Tumor
  • Taipei, Nehu District, Taiwan
    Tri-Service General Hospital
Apr 23, 2021

Refractory Solid Tumor, Hepatocellular Carcinoma, Malignant Solid Tumor Trial in Memphis (Atezolizumab, Sorafenib, Bevacizumab)

Recruiting
  • Refractory Solid Tumor
  • +4 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Aug 4, 2022

The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD

Recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 25, 2022

The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or

Recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Oct 25, 2022

Metastatic Breast Cancer Trial in United States (Sorafenib, Letrozole)

Terminated
  • Metastatic Breast Cancer
  • Washington, District of Columbia
  • +3 more
Sep 21, 2021

Prostate Cancer Trial in Philadelphia (docetaxel, sorafenib tosylate)

Completed
Has Results
  • Prostate Cancer
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Feb 16, 2022

Metastatic Colorectal Cancer Trial in France (Nexavar (Sorafenib) and irinotecan (Campto))

Completed
  • Metastatic Colorectal Cancer
  • Nexavar (Sorafenib) and irinotecan (Campto)
  • Lille, France
  • +4 more
Jun 17, 2021

Hepatocellular Carcinoma Trial in Hong Kong (Durvalumab, Sorafenib, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Hong Kong, Hong Kong SAR, Hong Kong
    Humanity & Health Research Centre
Mar 16, 2022

Hepatocellular Carcinoma, Hepatoma Trial in Baltimore (sorafenib, LC Bead-TACE)

Completed
Has Results
  • Hepatocellular Carcinoma
  • Hepatoma
  • Baltimore, Maryland
    The Johns Hopkins Hospital
Oct 15, 2021

Hepatocellular Carcinoma, Hepatitis B, Hepatitis C Trial in Duarte, Singapore (MTL-CEBPA, Sorafenib)

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Duarte, California
  • +1 more
Feb 20, 2022

Hepatocellular Carcinoma Trial in Albuquerque (Sorafenib & Capecitabine)

Terminated
Has Results
  • Hepatocellular Carcinoma
  • Sorafenib & Capecitabine
  • Albuquerque, New Mexico
  • +2 more
May 11, 2021

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • HAIC
  • +8 more
  • Quanzhou, Fujian, China
  • +1 more
Jan 26, 2023

Differentiated Thyroid Cancer Trial in Philadelphia (Everolimus, Sorafenib)

Active, not recruiting
  • Differentiated Thyroid Cancer
  • Philadelphia, Pennsylvania
    Hospital of the University of Pennsylvania
Oct 18, 2021

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer Trial in

Completed
  • Acinar Cell Adenocarcinoma of the Pancreas
  • +4 more
  • sorafenib tosylate
  • +4 more
  • Aurora, Colorado
  • +1 more
Sep 8, 2022

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • TACE
  • +8 more
  • Quanzhou, Fujian, China
  • +3 more
Jan 29, 2023